Arbutus Biopharma Corp. (NASDAQ: ABUS) stock gained by 2.43% at last close whereas the ABUS stock price surges by 14.54% in the pre-market trading.Arbutus Biopharma Corporation is a publicly listed pharmaceutical firm whose primary goal is to find, develop, and commercialize a treatment for chronic hepatitis B virus (HBV) infection.
>> 7 Top Picks for the Post-Pandemic Economy <<
What is happening?
Five abstracts from ABUS will be presented at the European Association for the Study of the Liver’s International Liver Congress. Professor Man-Fung Yuen, Deputy Head of Department, Chief of Division of Gastroenterology and Hepatology, Master of Lap Chee, University of Hong Kong, and lead researcher of AB-729’s Phase 1a/1b clinical trial, gave an oral late-breaker presentation (Presentation LBO-2764) named, “Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust.
Read More
Professor Yuen stated that AB-729 continues to show substantial mean HBsAg decrease across all dosages and dosing intervals, as well as a positive safety and tolerability profile, with a persistent plateau phase.
Professor Yuen commented,
These findings continue to show that AB-729 reduces HBsAg in a consistent and comparable manner across all dosages and dosing intervals, according to Professor Yuen. Importantly, AB-729 was usually well accepted and safe. He feels that these findings encourage further research into AB-729 as a potential breakthrough in the treatment of chronic HBV.
>> 7 Top Picks for the Post-Pandemic Economy <<
Outcomes,
- At week 44, AB-729 dosed at 60 mg per 8 weeks had a mean HBsAg decrease of -1.87 log10 IU/mL, which was equivalent to 60 mg every 4 weeks.
- In 75 percent of treated patients, AB-729 reduced HBsAg levels below 100 IU/ml, and enhanced HBV-specific immune responses in 3/5 evaluable cases.
- HBV RNA and all HBsAg isoforms were reduced by AB-729, indicating wide target engagement.
- After 48 weeks of treatment, AB-729 showed a satisfactory safety and tolerability profile.
- Preclinical studies on AB-836 show that it has the potential to be more effective and have a better resistance profile than prior generation capsid inhibitors.
